A quantitative detection of Cardiotrophin‐1 in chronic heart failure by chemiluminescence immunoassay

Ping, Ying; Wang, Xuchu; Dai, Yibei; Wang, Danhua; Liu, Weiwei; Pan, Yu; Tao, Zhihua

doi:10.1002/jcla.23570

Cited by 8 publications

(9 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Alternatively, LIF stimulates several beneficial effects including reduction of collagen production and matrix metalloproteinase activity in cardiac fibroblasts, resulting in an inhibition of differentiation of cardiac fibroblast to myofibroblast [ 267 ]. Likewise, the role of CT-1 seems unclear as consistent with reports describing CT-1 as having a potent hypertrophic effect on cultured cardiomyocytes [ 268 ] in addition to cardioprotective effects such as promoting cardiomyocyte survival [ 269 ]. In conclusion, during the process of developing cardiac hypertrophy, cytokine release is increased in response to a variety of stress stimuli, including pressure overload, injury, and mediators like AT-II.…”

Section: Mediators Of Cardiac Remodelingmentioning

confidence: 78%

The Microenvironment of the Pathogenesis of Cardiac Hypertrophy

Bazgir

Nau

Nakhaei‐Rad

et al. 2023

Cells

View full text Add to dashboard Cite

Pathological cardiac hypertrophy is a key risk factor for the development of heart failure and predisposes individuals to cardiac arrhythmia and sudden death. While physiological cardiac hypertrophy is adaptive, hypertrophy resulting from conditions comprising hypertension, aortic stenosis, or genetic mutations, such as hypertrophic cardiomyopathy, is maladaptive. Here, we highlight the essential role and reciprocal interactions involving both cardiomyocytes and non-myocardial cells in response to pathological conditions. Prolonged cardiovascular stress causes cardiomyocytes and non-myocardial cells to enter an activated state releasing numerous pro-hypertrophic, pro-fibrotic, and pro-inflammatory mediators such as vasoactive hormones, growth factors, and cytokines, i.e., commencing signaling events that collectively cause cardiac hypertrophy. Fibrotic remodeling is mediated by cardiac fibroblasts as the central players, but also endothelial cells and resident and infiltrating immune cells enhance these processes. Many of these hypertrophic mediators are now being integrated into computational models that provide system-level insights and will help to translate our knowledge into new pharmacological targets. This perspective article summarizes the last decades’ advances in cardiac hypertrophy research and discusses the herein-involved complex myocardial microenvironment and signaling components.

show abstract

Section: Mediators Of Cardiac Remodelingmentioning

confidence: 78%

The Microenvironment of the Pathogenesis of Cardiac Hypertrophy

Bazgir

Nau

Nakhaei‐Rad

et al. 2023

Cells

View full text Add to dashboard Cite

show abstract

“…Biotin-labeled antibodies and acridinium ester-labeled antibodies were prepared following the same procedure as a previous study [26].…”

Section: Antibody Preparationmentioning

confidence: 99%

Different patterns of exosomal α‐synuclein between Parkinson's disease and probable rapid eye movement sleep behavior disorder

Yan

Zheng

et al. 2022

Euro J of Neurology

View full text Add to dashboard Cite

Background and purpose The insidious onset of Parkinson's disease (PD) makes early diagnosis difficult. Notably, idiopathic rapid eye movement sleep behavior disorder (iRBD) was reported as a prodrome of PD, which may represent a breakthrough for the early diagnosis of PD. However, currently there is no reliable biomarker for PD diagnosis. Considering that α‐synuclein (α‐Syn) and neuroinflammation are known to develop prior to the onset of clinical symptoms in PD, it was hypothesized that plasma total exosomal α‐Syn (t‐exo α‐Syn), neural‐derived exosomal α‐Syn (n‐exo α‐Syn) and exosomal apoptosis‐associated speck‐like protein containing a caspase activation and recruitment domain (ASC) may be potential biomarkers of PD. Methods In this study, 78 PD patients, 153 probable iRBD patients (pRBD) and 63 healthy controls (HCs) were recruited. α‐Syn concentrations were measured using a one‐step paramagnetic particle‐based chemiluminescence immunoassay, and ASC levels were measured using the Ella system. Results It was found that t‐exo α‐Syn was significantly increased in the PD group compared to the pRBD and HC groups (p < 0.0001), whilst n‐exo α‐Syn levels were significantly increased in both the PD and pRBD groups compared to HCs (p < 0.0001). Furthermore, although no difference was found in ASC levels between the PD and pRBD groups, there was a positive correlation between ASC and α‐Syn in exosomes. Conclusions Our results suggest that both t‐exo α‐Syn and n‐exo α‐Syn were elevated in the PD group, whilst only n‐exo α‐Syn was elevated in the pRBD group. Additionally, the adaptor protein of inflammasome ASC is correlated with α‐Syn and may facilitate synucleinopathy.

show abstract

“…Currently, CLIAs are increasingly being used in the biological analysis because of their extreme sensitivity, high specificity, efficient simplified detection procedures, and short assay time [ 13 ]. Therefore, we evaluated the performance of a CLIA to detect serum CHI3L1 according to the CLSI guidelines.…”

Section: Discussionmentioning

confidence: 99%

“…However, the results of the magnetic bead fluorescent immunoassay (MB-FIA) and the fluorescence immunochromatography assay (FICA) were not accurate enough [ 11 , 12 ]. With the characteristics of a short determination time and high specificity, the chemiluminescent immunoassay (CLIA) has been increasingly used in routine clinical applications [ 13 ]. Considering the important clinical value of a CLIA for the rapid and accurate quantification of CHI3L1, it is necessary to explore its analytical performance and clinical application.…”

Section: Introductionmentioning

confidence: 99%

“…However, the results of the magnetic bead fuorescent immunoassay (MB-FIA) and the fuorescence immunochromatography assay (FICA) were not accurate enough [11,12]. With the characteristics of a short determination time and high specifcity, the chemiluminescent immunoassay (CLIA) has been increasingly used in routine clinical applications [13].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Analytical and Clinical Evaluation of a Chemiluminescent Immunoassay to Detect Serum Chitinase-3-like Protein 1 in HBV-Related Liver Diseases

Liao,

Peng,

Huang

et al. 2024

International Journal of Analytical Chemistry

View full text Add to dashboard Cite

Serum chitinase-3-like protein 1 (CHI3L1) is a diagnostic marker for liver diseases, such as hepatocellular carcinoma (HCC). Herein, we aimed to evaluate the analytical performance of a chemiluminescent immunoassay (CLIA) for the quantitative detection of CHI3L1 and its application in hepatitis B virus (HBV)-related liver diseases. The CLIA for CHI3L1 detection presented good analytical performance, with a linear range of 1.50–2000.00 ng/mL and a detection limit of 0.98 ng/mL. To evaluate its clinical application, serum CHI3L1 levels were detected in 82 patients with chronic hepatitis B (CHB) and in 21 healthy controls. The patients with CHB and HCC had higher CHI3L1 levels than the healthy controls and the patients with CHB without HCC. However, CHI3L1 levels did not change significantly with the increase in liver fibrosis stages. The area under the receiver operating characteristic curve for the diagnosis of HBV-related HCC was 0.808, representing a moderate diagnostic value. Correlation analysis revealed a significant association between CHI3L1 and alpha-fetoprotein (AFP) levels, the fibrosis-4 (FIB-4) index, and the aspartate aminotransferase-to-platelet ratio index (APRI). In conclusion, compared with currently reported methods for CHI3L1 detection, the CLIA has a high sensitivity, a wide linear range, and an acceptable accuracy, precision, and reference intervals, making it valuable in the diagnosis of HBV-related HCC.

show abstract

A quantitative detection of Cardiotrophin‐1 in chronic heart failure by chemiluminescence immunoassay

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 8 publications

References 34 publications

The Microenvironment of the Pathogenesis of Cardiac Hypertrophy

The Microenvironment of the Pathogenesis of Cardiac Hypertrophy

Different patterns of exosomal α‐synuclein between Parkinson's disease and probable rapid eye movement sleep behavior disorder

Analytical and Clinical Evaluation of a Chemiluminescent Immunoassay to Detect Serum Chitinase-3-like Protein 1 in HBV-Related Liver Diseases

Contact Info

Product

Resources

About